Evidence map›Paper›PMID 39706882›Full record

ArticleNPJ Parkinson's disease2024

Biologically defined neuronal synuclein disease as a tool to advance drug development.

Gennaro Pagano, Tien Dam, Geoffrey A Kerchner, Wendy R Galpern, Milton Biagioni, Rajesh Karan, Danna Jennings, M Judith Peterschmitt, Tania Nikolcheva, Patrik Brundin

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gennaro PaganoRoche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland. gennaro.pagano@roche.com.
Tien DamNeumora Therapeutics, Watertown, MA, USA.
Geoffrey A KerchnerRoche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Wendy R GalpernJanssen Research & Development, LLC, Cambridge, MA, USA.
Milton BiagioniUCB Pharma, Brussels, Belgium.
Rajesh KaranGlobal Drug Development, Novartis Pharma AG, Basel, Switzerland.
Danna JenningsDenali Therapeutics Inc., South San Francisco, CA, USA.
M Judith PeterschmittSanofi, Clinical Development Neurology, Cambridge, MA, USA.
Tania NikolchevaProduct Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Patrik BrundinRoche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39706882
PMCPMC11662015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.